Epidermal growth factor receptor tyrosine kinase mutant (EGFR TK mutant (EGFR TKMs))

Epidermal growth factor receptor tyrosine kinase mutants refer to variant forms of the EGFR gene (also known as ERBB1 or HER1) that harbor activating or resistance-associated mutations in its tyrosine kinase domain, most commonly spanning exons 18 to 21. EGFR is a transmembrane receptor with intrinsic tyrosine kinase activity that, upon ligand binding and subsequent dimerization, triggers autophosphorylation events leading to activation of several downstream signaling pathways (including MAPK and PI3K/Akt) that regulate cell proliferation, survival, migration, and differentiation[1][2][3]. Mutations within the kinase domain increase constitutive signaling activity, promote oncogenesis, and alter sensitivity or resistance to specific EGFR-targeted therapies[3][4][5]. EGFR tyrosine kinase mutants are validated therapeutic targets in many epithelial cancers, particularly non-small cell lung cancer, and are the focus of both small molecule and antibody-based targeted therapies designed to inhibit aberrant EGFR signaling[4][5]. Selection of patients for EGFR-targeted drugs is routinely guided by EGFR mutational analysis as a key predictive biomarker, but challenges including drug resistance mutations and on-target side effects must be considered in the clinical setting[4][6].

Other names

EGFR mutantMutant EGFREGFR TKD mutantsMutant epidermal growth factor receptor tyrosine kinase

Small molecule tyrosine kinase inhibition (EGFR TKIs), Monoclonal antibody inhibition of extracellular domains, Irreversible (covalent) and reversible kinase inhibition, Inhibition of kinase activity via ATP-binding site blockage